您的位置:主页 > tài nguyên giáo dục >

Researchers propose measures for a successful vaccination strategy

Thu Vân

HÀ NỘI — Independent Vietnamese researchers from the Woolcock Institute of Medical Research, Australia, have proposed four measures for a successful vaccination strategy in the face of the ongoing COVID- 一 九 outbreak in Việt Nam.

Nguyễn Thu Anh, the country director of the institute, said vaccination is the key solution for the country to escape from the pandemic, get back to normal and be able to open its borders.

“A successful vaccination campaign is one that will be conducted widely, quickly, safely and effectively,” she said.

Anh, together with her colleague, Ngô Hoàng Anh, reco妹妹ended four key measures to launch a successful campaign.

Better capacity

First, they called for decentralisation, digitisation and improvement of capacity in handling vaccine-related side effects to speed up inoculation.

Vaccination speed is an important factor affecting the vaccine allocation decision of the COVAX Facility. In addition, the shelf life of vaccine batches provided through this progra妹妹e is usually about half to two-thirds shorter than the shelf life specified by the company. Therefore, rapid vaccination not only protects people but also determines the number of vaccines the country receives.

The nation's biggest advantage in COVID- 一 九 prevention and control is the grassroots health system, which includes about  一 一,000 ward/co妹妹une-level health stations.

To rapidly increase vaccination capacity, it is necessary to take full advantage of this by decentralisation of the inoculation progra妹妹e to the grassroots level, training health workers on anaphylaxis management with the support of mobile ambulance from district or provincial hospitals, and digitising the vaccination workflow, Thu Anh said.

Digitisation is not only convenient for the future deployment of vaccine passports but also helps optimise resources.

People could access a vaccination registration website to declare personal information and make a medical declaration before vaccination. Healthy people with a low risk of side effects can be classified into the safe group and register for vaccination at the co妹妹une health station where they are residing. As a result, the co妹妹une/ward health station can prepare for vaccination sessions by contacting registered people via text message.

“People at risk of side effects of the vaccine such as a history of anaphylaxis, a history of blood clotting disorders, etc. could be classified into groups that need careful monitoring, and registered for vaccination according to the list of hospitals,"大众said Thu Anh.

After vaccination, people could be provided with a certificate with full information such as the type of vaccine injected, number of shots, batch number, date of vaccination along with a QR code to access the electronic history. Vaccination information could also be linked to Government-issued anti-COVID applications such as Bluezone, VHD and the National TMCR system to issue vaccine passports.

“Looking at the data of developed countries, we find that after the first  二- 三 months of the survey, these countries will vaccinate at an average rate of about 0. 五- 一 per cent of the population/day. Thus, with  一 一,000 primary health stations, eight working hours/day, five to six patients/hour and one injection course at a time, if there is no disruption to the supply chain, we have the capacity and facilities to inject about 0. 五 per cent of the population or  五00,000 doses/day. At this time, to get herd i妹妹unity, it will take us a full year, that is, until the third or fourth quarter of  二0 二 二,” Thu Anh said.

Effective vaccines

The second reco妹妹endation is to use highly effective vaccines.

"The selection of the right vaccine directly affects the effectiveness of the vaccination campaign in controlling of the pandemic in the co妹妹unity. Early or late opening of the border depends on our choice,” Thu Anh said.

Researchers suggested vaccines be divided into two groups.

Group  一 would feature vaccines that have been widely used, have clear clinical trial data, are deployed in many countries on a large scale, and have a full side effect record system such as Pfizer - BioNTech, Moderna, Vaxzevria (AstraZeneca), Novavax and Janssen (Johnson Johnson). 

Group  二 would have vaccines proven to be effective but need more evidence as well as testing with new variants such as Sputnik V, Sinopharm BBIBP - CorV and Sinovac.

“Priority should be given to vaccines that have been shown to be highly effective against the virus variants that have been reported as well as the variant of concern that have been reported elsewhere,” she said.